In another study using the same system to access pertuzumab in the neoadjuvant setting, which at the time was not yet approved in Quebec, in combination with neoadjuvant chemotherapy and trastuzumab in early human epidermal growth factor receptor 2 (HER2-positive) breast cancer, we demonstrated increased pathological complete response rate [21]. Here, ERBB2 is linked to breast carcinoma.